Krystal Biotech, Inc. Overview
Pro stress-test →Krystal Biotech is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company commercializes VYJUVEK for the treatment of dystrophic epidermolysis bullosa (DEB).
Strategic Profile
Pro stress-test →The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. Vyjuvek delivered $97.8M revenue in Q3 2025 with 96% gross margin and a new at-home use label.
Competitive Landscape
Pro stress-test →Key competitors in the gene therapy and rare disease space include Verve Therapeutics, Caribou Biosciences, Regenxbio, Abeona Therapeutics, and others. Krystal's proprietary redosable HSV vector platform and Vyjuvek's commercial success differentiate it in the rare genetic disease market.
Industry Context
Krystal Biotech, Inc. operates in Biotechnology / Gene Therapy / Rare Genetic Diseases.
Key facts
Founded: 2016 · Headquarters: Pittsburgh, Pennsylvania · Employees: 275 · Revenue: $373M · Market cap: $8.1B